Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 4/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 14/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12189590 | 0.78 | HSD11B1 (0.44) | S1PR4SCN10A | |
| SCHEMBL320779 | 0.78 | HTR2A (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30707530 | 0.78 | HTR2A (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7846062 | 0.77 | S1PR4 (0.45) | S1PR4SCN10A | |
| SCHEMBL12512413 | 0.76 | LMNA (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL25450675 | 0.74 | TP53 (0.41) | — | |
| SCHEMBL25450664 | 0.74 | TRPA1 (0.48) | — | |
| SCHEMBL14686270 | 0.74 | DPP4 (0.48) | — | |
| SCHEMBL12434794 | 0.73 | L3MBTL1 (0.46) | — | |
| SCHEMBL278031 | 0.73 | S1PR4 (0.45) | S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | S1PR4 2762/4885PSEN1 1091/4885PSEN2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.